Currently out of the existing stock ratings of Serge Belanger, 509 are a BUY (92.21%), 43 are a HOLD (7.79%).

Serge Belanger

Work Performance Price Targets & Ratings Chart

Analyst Serge Belanger, currently employed at NEEDHAM, carries an average stock price target met ratio of 41.46% that have a potential upside of 65.07% achieved within 365 days.

Serge Belanger’s has documented 1,095 price targets and ratings displayed on 41 stocks. The coverage is on Healthcare, Technology, Industrials sectors.

Most recent stock forecast was given on BCRX, BioCryst Pharmaceuticals.

Wall Street Analyst Serge Belanger

Analyst best performing recommendations are on GRAY (GRAYBUG VISION).
The best stock recommendation documented was for KALV (KALVISTA PHARMACEUTICALS) at 1/26/2021. The price target of $32 was fulfilled within 14 days with a profit of $15.65 (95.72%) receiving and performance score of 68.37.

Average potential price target upside

of $494.29 (83.35%) on PTX (PERNIX THERAPEUTICS HOLDINGS).
of $81.17 (80.6%) on VRCA (VERRICA PHARMACEUTICALS).
of $21.59 (51.53%) on CYTK (CYTOKINETICS).

AMPH Amphastar P CLSD Clearside Biomedical COLL Collegium Pharmaceutical CORI Corium International FLXN Flexion Therapeutics HRTX Heron Therapeuti KALV Kalvista Pharmaceuticals LQDA Liquidia Technologies OMER Omeros PCRX Pacira Pharmaceuticals RVNC Revance The VRCA Verrica Pharmaceuticals ZGNX Zogenix AERI Aerie Pharmaceuticals AKBA Akebia Ther BCRX BioCryst Pharmaceuticals CRXT Clarus Therapeutics Holdings CYTK Cytokinetics GRAY Graybug Vision PHAS PhaseBio Pharmaceuticals TCDA Tricida TRVI Trevi Therapeutics XENE Xenon Pharmaceuticals ESPR Esperion Therapeutics PTX Pernix Therapeutics Holdings CRMD CorMedix AMAG AMAG Pharmaceuticals ARQT Arcutis Biotherapeutics EOLS Evolus VRDN Viridian Therapeutics ZYNE Zynerba Pharmaceuticals DICE Dice Molecules Holdings LLC MLTX MoonLake Immunotherapeutics NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares ALDR Alder BioPharmaceuticals OCUL Ocular Therapeutix ADMS Adamas Pharmaceuticals CLS Celestica CR Crane Company DERM Journey Medical Corp OCS Oculis Holding AG Ordinary shares

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Glen Santangelo (BARCLAYS)

Hold Since 08-Apr-2026

$23

$-0.18 (-0.78%)

$20

24 days ago
(18-Aug-2026)

5/8 (62.5%)

$1.66 (7.78%)

Please subscribe to see extended stock data

David Amsellem (PIPER SANDLER)

Hold Since 21-Mar-2025

$20

$-3.18 (-13.72%)

$21

1 months 4 days ago
(07-Aug-2026)

13/20 (65%)

$-0.78 (-3.75%)

263

Please subscribe to see extended stock data

Jason Gerberry (BAML)

Hold Since 26-Aug-2025

$20

$-3.18 (-13.72%)

2 months 13 days ago
(29-Jun-2026)

2/3 (66.67%)

$-0.71 (-3.43%)

Please subscribe to see extended stock data

Cerena Chen (WELLS FARGO)

Buy Since 22-Nov-2024

$19

$-4.18 (-18.03%)

$35

3 months 28 days ago
(14-May-2026)

1/3 (33.33%)

$1.7 (9.83%)

Please subscribe to see extended stock data

Serge Belanger (NEEDHAM)

Buy Since 22-Oct-2025

$30

4 months 3 days ago
(08-May-2026)

9/13 (69.23%)

$9.77 (48.29%)

299

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Serge Belanger most bullish on?

Potential upside of $41.34 has been obtained for LQDA (LIQUIDIA TECHNOLOGIES)

Which stock is Serge Belanger most reserved on?

Potential downside of -$0 has been obtained for KALV (KALVISTA PHARMACEUTICALS)

What Year was the first public recommendation made by Serge Belanger?

On 2009